Curevac announces positive data on joint covid-19 and flu mrna vaccine development programs

Promising covid-19 and flu modified mrna vaccine candidates identified based on positive preliminary data from ongoing phase 1 studies all candidates use curevac's advanced second-generation mrna backbone optimized to achieve improved mrna translation and strong immune responses at low doses the preliminary results provide strong evidence of technology for curevac's mrna platform; curevac and partner gsk plan to advance modified mrna covid-19 and flu candidates to the next stages of clinical development covid-19: monovalent modified mrna vaccine candidate cv0501, encoding omicron variant ba.1, successfully boosted antibody titers against ba.1 and the wild type variants and was generally well tolerated across all tested dose groups flu: monovalent modified mrna vaccine candidate flu-sv-mrna successfully boosted antibody titers against matching flu strain; even at lowest dose, titers were at least in line with a licensed comparator; flu-sv-mrna was well tolerated across all tested dose groups curevac to host a webcast and conference call on january 6, 2023 at 3:00 p.m. cet / 9:00 a.m.
CVAC Ratings Summary
CVAC Quant Ranking